{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:31:06Z","timestamp":1769549466244,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Serum biomarker testing for multiple sclerosis has been increasing in popularity in research and clinical practice. Little evidence is available on influences of disease modifying therapy on serum biomarker levels. Interpretation of clinically available serum biomarkers in the context of each individual patient poses a greater challenge in this context. This study focuses on correlations between clinical variables and unique profile of serum biomarkers in the context of anti-CD20 treatment by ocrelizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cohort of multiple sclerosis patients without relapse in the last 12\u00a0months and the following 3\u00a0months who received serum biomarker testing with the Octave MSDA (Multiple Sclerosis Disease Activity) panel of 18 biomarkers between June 2023 and June 2024 was identified at the UCI Multiple Sclerosis Center. Clinical data was collected retrospectively. Data preparation, analysis and visualization were performed using R.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 118 MS patients without recent acute inflammatory activity were included (63 untreated and 55 on ocrelizumab). Longitudinal immunoglobulin data were available for 48 patients receiving ocrelizumab. Age-adjusted analyses revealed significantly elevated B-cell activating factor (BAFF) levels in the ocrelizumab group. In these patients, BAFF correlated inversely with IgG and IgA\u2014but not IgM\u2014levels. IgG declined over time in patients treated with ocrelizumab, with higher BAFF levels predicting lower IgG and IgA independent of treatment duration. Patients with elevated BAFF exhibited both lower baseline IgG and a more rapid IgG decline compared to those with lower BAFF. Elevated BAFF also correlated positively with markers of neuroaxonal injury, including neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP), Myelin oligodendrocyte glycoprotein (MOG), as well as with multiple pro-inflammatory biomarkers such as osteopontin (OPN), CXCL9, CXCL13, CCL20, TRAIL-R1, and CDCP1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study provides insight into unique biomarker profile in patients on ocrelizumab. Increased BAFF was associated with lower IgG and IgA levels, biomarkers of neuroaxonal damage and inflammation in MS patients without recent acute inflammatory activity on ocrelizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-025-03632-y","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T01:34:55Z","timestamp":1764293695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab"],"prefix":"10.1186","volume":"23","author":[{"given":"Anastasia","family":"Chumakova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Demetriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"3632_CR1","doi-asserted-by":"publisher","first-page":"101009","DOI":"10.1016\/j.lanepe.2024.101009","volume":"44","author":"M Di Filippo","year":"2024","unstructured":"Di Filippo M, Gaetani L, Centonze D, et al. Fluid biomarkers in multiple sclerosis: from current to future applications. Lancet Reg Health. 2024;44:101009. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101009.","journal-title":"Lancet Reg Health"},{"key":"3632_CR2","doi-asserted-by":"publisher","first-page":"109688","DOI":"10.1016\/j.clim.2023.109688","volume":"253","author":"T Chitnis","year":"2023","unstructured":"Chitnis T, Foley J, Ionete C, et al. Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Clin Immunol. 2023;253:109688. https:\/\/doi.org\/10.1016\/j.clim.2023.109688.","journal-title":"Clin Immunol"},{"issue":"3","key":"3632_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"issue":"2","key":"3632_CR4","doi-asserted-by":"publisher","first-page":"e200094","DOI":"10.1212\/NXI.0000000000200094","volume":"10","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Bar-Or A, Weber MS, et al. Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(2):e200094. https:\/\/doi.org\/10.1212\/NXI.0000000000200094.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3632_CR5","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","volume":"14","author":"J de S\u00e8ze","year":"2023","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, et al. Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol. 2023;14:1004795. https:\/\/doi.org\/10.3389\/fimmu.2023.1004795.","journal-title":"Front Immunol"},{"key":"3632_CR6","unstructured":"Centers for Medicare and Medicaid Services. CLIA Verification of Performance Specifications. 2023. Available at: https:\/\/www.cms.gov\/regulations-and-guidance\/legislation\/clia\/downloads\/6064bk.pdf."},{"key":"3632_CR7","doi-asserted-by":"publisher","unstructured":"Qureshi F, Hu W, Loh L, Patel H, DeGuzman M, Becich M, Rubio da Costa F, Gehman V, Zhang F, Foley J, Chitnis T. Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Proteomics Clin Appl. 2023;17(3):e2200018. https:\/\/doi.org\/10.1002\/prca.202200018. Epub 2023 Mar 20. PMID: 36843211.","DOI":"10.1002\/prca.202200018"},{"issue":"6","key":"3632_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.medj.2023.05.001","volume":"4","author":"A Schuckmann","year":"2023","unstructured":"Schuckmann A, Steffen F, Zipp F, Bittner S, Pape K. Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis. Med. 2023;4(6):361-372.e3. https:\/\/doi.org\/10.1016\/j.medj.2023.05.001. Epub 2023 May 25 PMID: 37236189.","journal-title":"Med"},{"issue":"5","key":"3632_CR9","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s10072-022-06582-y","volume":"44","author":"S Saidha","year":"2023","unstructured":"Saidha S, Bell J, Harold S, Belisario JM, Hawe E, Shao Q, et al. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis. Neurol Sci. 2023;44(5):1515\u201332. https:\/\/doi.org\/10.1007\/s10072-022-06582-y. Epub 2023 Jan 17. PMID: 36648561; PMCID: PMC9843103.","journal-title":"Neurol Sci"},{"key":"3632_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60\u20135. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.009.","journal-title":"J Autoimmun"},{"key":"3632_CR11","doi-asserted-by":"publisher","first-page":"105009","DOI":"10.1016\/j.msard.2023.105009","volume":"79","author":"E Alvarez","year":"2023","unstructured":"Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023;79:105009. https:\/\/doi.org\/10.1016\/j.msard.2023.105009.","journal-title":"Mult Scler Relat Disord"},{"key":"3632_CR12","doi-asserted-by":"publisher","first-page":"1538555","DOI":"10.3389\/fimmu.2025.1538555","volume":"16","author":"L Li","year":"2025","unstructured":"Li L, Shen S, Shao S, Dang E, Wang G, Fang H, et al. The role of B cell\u2013activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances. Front Immunol. 2025;16:1538555. https:\/\/doi.org\/10.3389\/fimmu.2025.1538555.","journal-title":"Front Immunol"},{"issue":"4","key":"3632_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/25785826.2022.2094592","volume":"45","author":"K Tsuboi","year":"2022","unstructured":"Tsuboi K, Noguchi K, Kitano M, Furukawa T, Hashimoto T, Azuma N, et al. Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis. Immunol Med. 2022;45(4):238\u201343. https:\/\/doi.org\/10.1080\/25785826.2022.2094592. Epub 2022 Jul 8. PMID: 35802795.","journal-title":"Immunol Med"},{"issue":"14","key":"3632_CR14","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1177\/13524585231204122","volume":"29","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Atkinson J, Burd CE, Graves J, Segal BM. Biological aging in multiple sclerosis. Mult Scler. 2023;29(14):1701\u20138. https:\/\/doi.org\/10.1177\/13524585231204122. PMID: 37877740; PMCID: PMC10843499.","journal-title":"Mult Scler"},{"issue":"4","key":"3632_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1128\/CMR.00046-17","volume":"30","author":"J Sakai","year":"2017","unstructured":"Sakai J, Akkoyunlu M. The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev. 2017;30(4):991\u20131014. https:\/\/doi.org\/10.1128\/CMR.00046-17.","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"3632_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00415-025-13133-w","volume":"272","author":"L Davies","year":"2025","unstructured":"Davies L, Shehadeh R, Watkins WJ, et al. Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis. J Neurol. 2025;272(6):415. https:\/\/doi.org\/10.1007\/s00415-025-13133-w.","journal-title":"J Neurol"},{"key":"3632_CR17","doi-asserted-by":"publisher","first-page":"1500763","DOI":"10.3389\/fneur.2024.1500763","volume":"15","author":"AA Fernandes","year":"2025","unstructured":"Fernandes AA, Neves AL, Ferro D, Seabra M, Mendon\u00e7a T, Dos Reis RS, et al. Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study. Front Neurol. 2025;15:1500763. https:\/\/doi.org\/10.3389\/fneur.2024.1500763.","journal-title":"Front Neurol"},{"issue":"3","key":"3632_CR18","doi-asserted-by":"publisher","first-page":"e200211","DOI":"10.1212\/NXI.0000000000200211","volume":"11","author":"A Langer-Gould","year":"2024","unstructured":"Langer-Gould A, Li BH, Smith JB, Xu S. Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol Neuroimmunol Neuroinflamm. 2024;11(3):e200211. https:\/\/doi.org\/10.1212\/NXI.0000000000200211. Epub 2024 Mar 20. PMID: 38507657; PMCID: PMC10959169.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"3632_CR19","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F Mackay","year":"2009","unstructured":"Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491\u2013502.","journal-title":"Nat Rev Immunol"},{"key":"3632_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12865-014-0028-1","volume":"15","author":"AL Fedele","year":"2014","unstructured":"Fedele AL, Tolusso B, Gremese E, et al. Memory B cell subsets and plasmablasts are lower in early than in long-standing rheumatoid arthritis. BMC Immunol. 2014;15:28. https:\/\/doi.org\/10.1186\/s12865-014-0028-1.","journal-title":"BMC Immunol"},{"issue":"2","key":"3632_CR21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI18025","volume":"112","author":"DT Avery","year":"2003","unstructured":"Avery DT, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112(2):286\u201397.","journal-title":"J Clin Invest"},{"issue":"5","key":"3632_CR22","doi-asserted-by":"publisher","first-page":"e122728","DOI":"10.1172\/jci.insight.122728","volume":"4","author":"PJ Maglione","year":"2019","unstructured":"Maglione PJ, Gyimesi G, Cols M, et al. BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency. JCI Insight. 2019;4(5):e122728. https:\/\/doi.org\/10.1172\/jci.insight.122728.","journal-title":"JCI Insight"},{"key":"3632_CR23","doi-asserted-by":"publisher","first-page":"622114","DOI":"10.3389\/fimmu.2020.622114","volume":"11","author":"EM Matson","year":"2021","unstructured":"Matson EM, Abyazi ML, Bell KA, Hayes KM, Maglione PJ. B cell dysregulation in common variable immunodeficiency interstitial lung disease. Front Immunol. 2021;11:622114. https:\/\/doi.org\/10.3389\/fimmu.2020.622114.","journal-title":"Front Immunol"},{"key":"3632_CR24","doi-asserted-by":"publisher","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721\u2013731. https:\/\/doi.org\/10.1016\/S0140-6736(10)61354-2.","DOI":"10.1016\/S0140-6736(10)61354-2"},{"issue":"4","key":"3632_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nrneurol.2014.48","volume":"10","author":"E Bible","year":"2014","unstructured":"Bible E. Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis. Nat Rev Neurol. 2014;10(4):182. https:\/\/doi.org\/10.1038\/nrneurol.2014.48. Epub 2014 Mar 18. PMID: 24638130.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"3632_CR26","doi-asserted-by":"publisher","first-page":"e200083","DOI":"10.1212\/NXI.0000000000200083","volume":"10","author":"S Ho","year":"2023","unstructured":"Ho S, Oswald E, Wong HK, et al. Ocrelizumab treatment modulates B-cell regulating factors in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(2):e200083. https:\/\/doi.org\/10.1212\/NXI.0000000000200083.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"3632_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12974-023-02922-7","volume":"20","author":"K Gupta","year":"2023","unstructured":"Gupta K, Kesharwani A, Rua S, et al. BAFF blockade in experimental autoimmune encephalomyelitis reduces inflammation in the meninges and synaptic and neuronal loss in adjacent brain regions. J Neuroinflammation. 2023;20(1):229. https:\/\/doi.org\/10.1186\/s12974-023-02922-7.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"3632_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","volume":"13","author":"L Kappos","year":"2014","unstructured":"Kappos L, et al. Atacicept in relapsing multiple sclerosis: results of a randomized, placebo-controlled, phase II trial. Lancet Neurol. 2014;13(4):353\u201363.","journal-title":"Lancet Neurol"},{"issue":"737","key":"3632_CR29","doi-asserted-by":"publisher","first-page":"eadi0295","DOI":"10.1126\/scitranslmed.adi0295","volume":"16","author":"AA Wang","year":"2024","unstructured":"Wang AA, Luessi F, Neziraj T, et al. B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans. Sci Transl Med. 2024;16(737):eadi0295. https:\/\/doi.org\/10.1126\/scitranslmed.adi0295.","journal-title":"Sci Transl Med"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03632-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03632-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03632-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:54:43Z","timestamp":1767477283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-025-03632-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3632"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03632-y","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board (UCI IRB #5318). Informed consent requirements were waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}